91.64MMarket Cap-868P/E (TTM)
2.300High1.850Low3.57MVolume2.280Open2.260Pre Close7.24MTurnover8.58%Turnover RatioLossP/E (Static)48.88MShares26.35052wk High0.53P/B77.94MFloat Cap1.90052wk Low--Dividend TTM41.57MShs Float26.350Historical High--Div YieldTTM19.91%Amplitude0.590Historical Low2.028Avg Price1Lot Size
Cabaletta Bio Stock Forum
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
Cabaletta Bio (Nasdaq: CABA) announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, featuring new and updated clinical data on CABA-201, their 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The presentations will cover:
1. An oral presentation on the safety and efficacy of C...
Larger Image: tradingview.com...
$Cabaletta Bio (CABA.US)$
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
$Cabaletta Bio (CABA.US)$
No comment yet